Responses
Clinical and epidemiological research
Extended report
MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
Compose a Response to This Article
Other responses
No responses have been published for this article.